 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
2008
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Marilee Andrew Effect of Cranberry Juice on Population Pharmacokinetics of Amoxicillin and Cefaclor |
| Julie ANTIC Some Stochastic Algorithms For The Smooth Non Parametric (SNP) Estimator |
| Daren Austin Use of mechanistic models to estimate target antigen load for monoclonal antibodies |
| Michael Barras Individualized compared with conventional dosing of enoxaparin. |
| Jeff Barrett Enhancing Methotrexate Pharmacotherapy in Children with Cancer: A Decision Support System Integrating Real-time PK/PD Modeling and Simulation with Patient Medical Records |
| Paul Baverel Covariate Model Building Method for Nonparametric Estimation Method in NONMEM VI: Application to Simulated Data |
| Caroline Bazzoli Population pharmacokinetics of AZT and its active metabolite AZT-TP in HIV patients: joint modelling and design optimisation |
| Corina Becker Whole-Body Physiologically-based Pharmacokinetic (WB-PBPK) Population Modelling to Simulate the Influence of Weight and Age on the Pharmacokinetics (PK) of a combined Oral Contraceptive Containing Drospirenone (DRSP) and Ethinylestradiol (EE) |
| Misba Beerahee Clinical Trial Simulation to Estimate the Sample Size for Investigation of the Impact of a Drug A on the Pharmacokinetics of Methotrexate, a common co-medication used in Rheumatoid Arthritis (RA) |
| Aliénor Bergès Using VT (total volume of distribution from PET) in estimating the PK-Receptor Occupancy relationship in the absence of reference regions. |
| Martin Bergstrand Modeling of gastro-intestinal tablet transit and its’ effect on drug release and absorption for felodipine extended release tablet under fed or fasting conditions |
| Julie Bertrand Properties of different tests to detect the effect of a genetic covariate on pharmacokinetic parameters using the SAEM algorithm for several designs |
| Robert Bies A comparison of a genetic algorithm based automated search algorithm to standard stepwise approach for population pharmacokinetics using NONMEM. |
| Martin Boucher A Bayesian Meta-Analysis of Longitudinal Data in Placebo Controlled Studies with Naproxen |
| René Bruno Modeling and simulation to assess the use of change in tumor size as primary endpoint in Phase II studies in oncology |
| Massimo Cella Randomisation to exposure in early paediatric trials: an analysis on the influence of the dose on the heterogeneity in the response to abacavir. |
| Pascal Chanu Decisive support of Modeling & Simulation for getting drug approval in the context of safety concern on the drug class |
| Chao Chen Population PK/PD modelling of functional receptor occupancy in a first-time-in human study |
| Chao Chen Population modeling of the relationship between ropinirole systemic exposure and efficacy in Parkinson’s disease |
| Marylore Chenel How to show average bioequivalence of concentrations in a test sample with a reference population pharmacokinetic model? |
| Marylore Chenel Optimal design of QTc interval measurements for circadian rhythm determination |
| Jason Chittenden Phoenix platform, WinNonlin, Trial Simulator, WinNonlin AutoPilot, and PKS (a PK/PD data repository) |
| Laurent Claret A modeling framework to simulate Xeloda dose intensity and survival in colorectal cancer |
| Helena Colom Population pharmacokinetics of Ganciclovir following Valganciclovir in solid organ transplant recipients infected by cytomegalovirus |
| Emmanuelle Comets Modelling is seldom used to describe pharmacokinetics in phase I clinical trials |
| Cian Costello A Time Scaling Approach to Develop an In Vitro-In Vivo Correlation (IVIVC) Model Using a Convolution-Based Technique |
| Meindert Danhof Implementing Receptor Theory in PK-PD Modeling |
| Rik de Greef Modeling and Simulation to Integrate Efficacy and Safety Data Following Full Development: a Case Study in Schizophrenia and Bipolar Disorder |
| Marion Dehez Optimal window design of blood pressure time measurements in hypertensive dippers and non-dippers using ABPM: Application of the compound D-optimality approach. |
| Francesca Del Bene Evaluating the Influence of Different Sources of Variability in the PK/PD Tumor Growth Inhibition (TGI) Model |
| Xavier Delavenne Assessment of pharmacokinetic variability of fondaparinux in 809 patients treated after major orthopedic surgery: the POP-A-RIX study |
| Paolo Denti Comparison of Different Population Analysis Approaches to the IVGTT Glucose Minimal Model |
| Vivek Dua Automatic Selection of Optimal Configuration of Artificial Neural Networks |
| Anne Dubois Population analysis of plasma and intracellular pharmacokinetics of indinavir in HIV-1 infected patients with a stable antiretroviral therapy |
| Stephen Duffull A system model for the clotting cascade challenges clinical management of snake bites. |
| Mike Dunlavey Simplified programming of population model user interfaces |
| Yumi Emoto Evaluation of Population PK/PD for Osteoporosis during a Vitamin D3 (1,25(OH)2D3) Derivative Therapy |
| Samuel Fanta Population Pharmacokinetics of Cyclosporine in Paediatric Renal Transplant Recipients |
| Colm Farrell Hands-On Demonstration of PDx-Pop® v3.0; Tools for Expediting Population Analysis |
| Carlos Fernandez-Teruel Simulations of bioequivalence trials using physiological-pharmacokinetic in single dose and steady state scenarios. Which scenarios are refusable? |
| Geraldine Ferron PK and PK/PD modeling of CB1 blocker antagonism of THC induced CNS and Heart Rate effect |
| Nicolas Frances Modeling of longitudinal tumor size data in clinical oncology studies of drugs in combination |
| Monika Frank Nevirapine - Population pharmacokinetic model building and simulation for mothers and newborns |
| Lena Friberg Modeling and Simulation of the Asenapine Exposure-Response and Drop-Out in Acute Schizophrenia |
| Lena Friberg Scaling the Time-Course of Myelosuppression from Rats to Patients with a Semi-Physiological Model |
| María José García Sánchez Population Pharmacokinetics of Efavirenz in HIV-infected patients: Pharmacogenetic analysis |
| Maria Garrido Simultaneous population pharmacodynamic modelling of the growth hormone and insulin-like growth factor-I effects after deep subcutaneous administration of Lanreotide Autogel® in acromegalic patients. Application of Nonparametric estimation method in NONMEM |
| Maria Garrido Biopharmaceutic and pharmacodynamic characterization of the in vitro anti-proliferative effect of new delivery systems of Cisplatin |
| Clare Gaynor A Differential Equations Approach to In Vitro – In Vivo Correlation Modelling in NONMEM |
| Massimiliano Germani Nonparametric Modeling and Population Approach to the Individualized Heart Rate Correction of the QT Interval |
| Cyrus Ghobadi Pharmacokinetics of oral single-dose clomiphene citrate (CC) in polycystic ovary patient with anovulatory infertility |
| Ekaterina Gibiansky Indirect Response Models with Positive Feedback: Equations, Properties, and Possible Applications |
| Leonid Gibiansky Parameter Estimates of Population Models: Comparison of Nonmem Versions and Estimation Methods |
| Leonid Gibiansky Approximations of the Target-Mediated Drug Disposition Model and Identifiability of Model Parameters |
| Leonid Gibiansky Application of Identifiability Analysis Algorithm to Population PK of the Drug with Target-Mediated Drug Disposition |
| Ihab Girgis Bayesian Modeling of QT Interval: Focus on Baseline Measurements |
| Sophie Gisbert Analysing Raw Count data from an In Vitro Target Occupancy Assay to Select Doses for Human Safety/Tolerability Trial |
| Joga Gobburu How Disease Models can reduce late phase attrition rate to half by 2015 |
| Sylvain Goutelle A Population Pharmacokinetic Study of Plasma and Intrapulmonary Concentrations of Rifampin |
| Sylvain Goutelle Influence of Rifampin Pharmacokinetic Variability on Antibacterial Effect and Prevention of Resistance in Pulmonary Tuberculosis: a Simulation Study |
| Andreas Velsing Groth Alternative parameterisations of saturable (Emax) models allowing for nesting of non-saturable models |
| Phey Yen Han Informative Study Designs to Identify True Parameter-Covariate Relationships |
| Tae Han Alteration of glucose and insulin regulatory networks for the treatment of type 2 diabetes mellitus |
| Rich Haney Open Statistical Services |
| Rich Haney Accelerating the Rate of Adoption of New Pharmacometrics Platforms Using Formal Tools For Model Interconversion |
| Emma Hansson The Shape of the Myelosuppression Time-course is Related to the Probability of Developing Neutropenic Fever in Patients with Docetaxel-induced Grade IV Neutropenia |
| Emma Hansson Comparison of Inter-Occasion and Inter-Individual Variability in Chemotherapy- Induced Myelosuppression |
| Emilie Hénin Patient compliance estimated from pharmacokinetic sample: application to Imatinib |
| Tracy Higgins Simulation and Design Considerations for Noninferiority Trials in Phase II |
| Nick Holford Delayed response to hypoglycaemic agents and effect on progression of type 2 diabetes |
| Nick Holford Stuck in Modelling – Attempts to describe disease progress and the action of oral hypoglycaemic agents in type 2 diabetes |
| Andrew Hooker Parameter estimation in non-linear mixed effects models using interval analysis |
| Andrew Hooker Xpose and Perl Speaks NONMEM (PsN) |
| Andrew Hooker PopED |
| Carlos Hoyo-Vadillo Pharmacokinetics model for Nifedipine administered to Healthy Volunteers. |
| Carlos Hoyo-Vadillo Four Programs for Writing and Running Nonmem Scripts. |
| Alwin Huitema Application of modelling and simulation in clinical oncology |
| Matt Hutmacher Implications for animal-human scaling of the parallel elimination profile PK model |
| Laura Iavarone A Population PK model to evaluate variability in oral absorption using gamma scintigraphy |
| Ibrahim Ince Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling |
| Masoud Jamei Simcyp Simulator - a comprehensive platform and database for mechanistic modelling and simulation of oral drug absorption, tissue distribution, metabolism and elimination in healthy and disease populations using in vitro knowledge |
| Petra Jauslin Identification of the Mechanism of Action of a Glucokinase Activator from OGTT Data in Type 2 Diabetics Using an Integrated Glucose-Insulin Model |
| Roger Jelliffe The USC*PACK software for nonparametric adaptive grid (NPAG) population PK/PD modeling, and the MM-USCPACK clinical software for individualized drug regimens. |
| Daniel Jonker The pharmacokinetics of the once-daily human glucagon-like peptide-1 analogue, liraglutide, across 5 trials in healthy subjects and type 2 diabetics after single and multiple dosing |
| Mats Karlsson A Tutorial on Visual Predictive Checks |
| Ron Keizer A simple infrastructure and graphical user interface (GUI) for distributed NONMEM analysis on standard network environments |
| Ron Keizer Population PK-PD modeling of E7820 and α2-integrin expression on platelets in patients with solid tumors and lymphomas |
| Hyung Ki Kim The Effect of Study Design on Pharmacokinetics in Patients with Impaired Renal Function |
| Søren Klim Deconvolution of Insulin Secretion Rates |
| Søren Klim Linear Mixed Effects models based on Stochastic Differential Equations in R |
| Charlotte Kloft Launch of the Graduate Research Training (GRT) Program 'Pharmacometrics & Computational Disease Modelling' in Germany |
| Catherijne Knibbe Predictive Value of Allometric Scaling for Estimation of Propofol Clearance in Neonates, Infants and Adolescents |
| stijn Koolen Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer |
| Elke Krekels Development AND External validation of a model for Glucuronidation in children below 3 years of age using morphine as a model drug; towards a novel dosing paradigm. |
| Kevin Krudys Bridging Cardiovascular Risk from Clinical Trials to Real Life Population |
| Katharina Küster Matuzumab – Evaluation of the Population Pharmacokinetic Model and Analyses of the Covariate Impact on the Pharmacokinetic Profile |
| Brigitte Lacroix Exposure-response analysis of certolizumab pegol in Crohn’s disease population |
| Brigitte Lacroix Exposure-Response Modeling of the ACR20 Score in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol. |
| Brigitte Lacroix Population Pharmacokinetics of Brivaracetam in Patients with Partial Epilepsy |
| Bart Laurijssens Model-Based Analysis of a Longitudinal Binary Response as the Primary Analysis for a Phase II Study in Migraine Prophylaxis. |
| Christian Laveille Evaluation of the PK and PK-PD libraries of MONOLIX: A comparison with NONMEM |
| Marc Lavielle Analysing population PK/PD data with MONOLIX 2.4 |
| Robert Leary A Nonparametric Analogue to POSTHOC Estimates for Exploratory Data Analysis |
| Sergei Leonov Stochastic pharmacokinetic models: selection of sampling times |
| Micha Levi Relationship Between Serum Concentration of the Interleukin-6 Receptor Inhibitor, Tocilizumab (TCZ), and Disease Activity Score (DAS28) in Patients with Rheumatoid Arthritis |
| Otilia Lillin A population analysis on the effects of the CYP2D6 deficiency on pharmacokinetics and exposure of esmirtazapine in healthy volunteers. |
| Andreas Lindauer Population Pharmacokinetics of High-dose Carboplatin |
| Rocio Lledo Randomised dose controlled trials or concentration controlled trials when learning about drugs with narrow therapeutic index? |
| Rocio Lledo Impact of study design for characterising PKPD covariance and nonlinearity in exposure-dichotomous response relationships |
| Igor Locatelli Population Pharmacokinetics of Risperidone in Patients with Acute Schizophrenia |
| Mark Lovern Leveraging complicated PK/PD models for the development of a Bayesian adaptive Dose-ranging design. |
| Mark Lovern Development of a Bayesian Adaptive Sampling Time strategy for PK studies with constrained number of samples to ensure accurate estimates. |
| Viera Lukacova PBPK modeling of metoprolol and its metabolites |
| Viera Lukacova GastroPlus |
| Guangli Ma Pool Model versus Agonist-Antagonist Interaction Model for the Remoxipride Effect on Prolactin |
| Sarah McLeay Scaling propofol doses for the obese: is lean body weight the answer? |
| Guy Meno-Tetang The Use of Clinical Trial Simulation to investigate Bias in Crossover Studies with a Short Washout Period and no Placebo Arm: Application to Neuropathic Pain |
| François Mercier Simulation and evaluation of bivariate Beta distribution for interval response variables |
| Raymond Miller Exposure-Response Analysis of Longitudinal Adverse Event Data. |
| Glynn Morrish Using Body Composition Metrics to Predict Exposure Between Japanese and Caucasian Populations |
| Flora Musuamba-Tshinanu Limited sampling formulas and bayesian estimation for mycophenolic acid 12 hours Area Under the concentration-time Curve prediction in Stable renal transplant recipients co-medicated with cyclosporine or sirolimus |
| Flora Musuamba-Tshinanu Simultaneous Therapeutic Drug Monitoring Of Amikacin And Beta-Lactams In Intensive Care Unit Patients With Severe Sepsis Or Septic Shock Without Beta-Lactam Serum Concentration Monitoring |
| Ricardo Nalda-Molina Pharmacokinetic and Pharmacodynamic Model for Drug Induced Transient Transaminitis |
| PARTHA NANDY Relationship Between a PK/PD Parameter and Therapeutic Response of Ceftobiprole in Patients with Complicate Skin and Skin Structure Infection |
| Carmen Navarro Estimating the complete AUC and its standard error in sparse sampling designs. |
| Michael Neely Population Kinetics and Dynamics of Lopinavir in HIV-Infected Children |
| Elisabet Nielsen Developmental Pharmacokinetics of Gentamicin in Preterm and Term Neonates: Modelling and Simulation Based on Data from a Prospective Study |
| Gianluca Nucci Modelling and Simulation of Ketoconazole inhibition when co-administration time is not sufficient: role of CYP3A function recovery |
| Gianluca Nucci A sparse sample PK & PKPD approach to estimate the time course of antipsychotic-induced D2 occupancy |
| Joakim Nyberg Application of the optimal design approach to improve therapeutic drug monitoring for cyclosporine |
| Joakim Nyberg Dose and sample time optimization of drug candidate screening experiments |
| Joakim Nyberg Application of Optimal Design for Disease Progression Studies |
| Kayode Ogungbenro An Effective approach for Obtaining Optimal Sampling Windows for Population Pharmacokinetic Experiments |
| Ines Paule Model-based dose adaptation of capecitabine for prevention of severe hand-and-foot syndrome: in silico comparison with the standard method |
| Klas Petersson Transforming parts of a differential equations system to difference equations as a method for run-time savings in NONMEM VI |
| Etienne Pigeolet Granulocyte Colony Stimulating Factor Pharmacokinetics After Single and Repeated Administration of Several Doses. |
| Elodie Plan Maximum Likelihood Estimation Methods: Performances in Count Response Models Population Parameters |
| Italo Poggesi Evaluation of a basic PBPK model in preclinical species for which tissue compositions are unknown |
| Italo Poggesi Evaluation of direct population PKPD models for truncated concentration-response curves |
| Teun Post Disease System for osteoporosis: relating bone mineral density with measures of bone formation and resorption based on bone biology |
| Rogier Press Optimizing Calcineurin Inhibitor Exposure In De Novo Kidney Transplant Recipients |
| Richard Pugh Mango Solutions |
| Angelica Quartino Comparison Between using Continuous and Categorical Toxicity Data for Estimation with a Model for Continuous Data |
| Silke Retlich BI 1356 (proposed trade name ONDERO) pharmacokinetics and DPP-4 inhibition: Development of a target mediated PKPD model in type 2 diabetic patients |
| Silke Retlich Target mediated drug disposition model for the DPP-4 inhibitor BI1356 (proposed trade name ONDERO): Is the structure identifiable? |
| Sylvie Retout Design optimisation in nonlinear mixed effects models using cost functions: application to a joint model of infliximab and methotrexate pharmacokinetics |
| Benjamin Ribba Monolix benefits from external modules to manage complex ODE: Illustration with a population analysis of Irinotecan and its metabolites. |
| Jakob Ribbing Modelling the Dynamics of Glucose, Insulin, Insulin Sensitivity and Beta-Cells in Subjects with Insulin Resistance and Patients with Type 2 Diabetes |
| Elba Romero Extended Link Model to Describe the Impact of Chronic Antiepileptic Therapy on the Effects of Neuromuscular Blocking Agents. |
| Daniel Röshammar Population Pharmacokinetics of Efavirenz and MDR-1, CY2B6, and CYP3A5 Polymorphisms |
| Alberto Russu Dose escalation studies: a comparison between NONMEM and a novel Bayesian tool |
| David Salinger Mean Squared Error as Criterion for Sampling Schedule Optimization for Individual Dose Targeting in IV Busulfan |
| Rada Savic A novel bootstrap method for obtaining uncertainty measurement around the nonparametric distribution |
| Antonin Schmitt External validation of a model based on cystatin C to predict carboplatin clearance |
| Nabil Semmar Independent-model diagnostics for a priori identification and interpretation of outliers from a full pharmacokinetic database: correspondence analysis, Mahalanobis distance and Andrews curves |
| Catherine Sherwin Simulation and development of a netilmicin extended dosing regimen for extremely premature neonates. |
| Hanna Silber Improvement of the intravenous glucose tolerance test using optimal experimental design. |
| Monica Simeoni Modelling beta amyloid system: sensitivity analysis at steady state and in dynamic conditions. |
| Nicolas Simon Population Pharmacokinetics of Atazanavir in HIV-infected Patients |
| Jean Smeets A Mechanism-based Pharmacokinetic Model Describing the Interaction Between Sugammadex and Rocuronium in Patients with Normal and Impaired Renal Function |
| Eric Snoeck The challenge of modelling hepatitis C virus dynamics after long term treatment: Application of MONOLIX |
| Elena Soto A semi-mechanistic population pharmacokinetic/pharmacodynamic model for neutropenia following therapy with the new PLK-1 inhibitor BI 2536 and its application in clinical development |
| Joe Standing Predicting Paediatric Tobramycin Pharmacokinetics with Five Different Methods |
| Armel Stockis Levetiracetam exposure-response analysis in children with partial onset seizures |
| Joel Tarning Population pharmacokinetics of lumefantrine in pregnant women treated with co-artemether for uncomplicated falciparum malaria |
| David Ternant Development of anti-infliximab antibodies increases infliximab clearance in inflammatory bowel diseases |
| Kellie Turner Reduced Folate Carrier Single Nucleotide Polymorphism Associated with Methotrexate Clearance in Breast Cancer Patients |
| Saik Urien RfN, R for Nonmem: A graphical interface for Nonmem outputs |
| Jan-Stefan van der Walt Population pharmacokinetic models for lamivudine and nevirapine to assess drug concentrations obtained during therapeutic drug monitoring |
| Tamara van Steeg Assessment of the use of complex baseline models in preclinical safety screening: Application of the van der Pol oscillator model to describe heart rate effects in rats |
| Thuy Vu Time Course of Disease Status as a Predictor of Clinical Outcome in Parkinson’s Disease |
| Katarina Vučićević Estimation of Relative Bioavailability of Controlled-Release Carbamazepine Tablets Based on Routine TDM Data |
| Johan Wallin Population pharmacokinetics of tacrolimus in paediatric heamatopeitic stem cell transplantation |
| Wolfgang Weiss Hands-On Demonstrations of the Physiology-Based Pharmacokinetic Software, PK-Sim® |
| Justin Wilkins Bioequivalence, bootstrapping and case-deletion diagnostics in a biologic: a model-based analysis of the effect of formulation differences in a monoclonal antibody |
| Susan Willavize Dose Selection for Combination Drug Products |
| Susan Willavize Using M&S to Shorten the Repeating Cycle of the Early Drug Development Process: A Case Study |
| Rujia Xie Relationship between the Dose of Recombinant Human Growth Hormone (rhGH) and Insulin Growth Factor-1 (IGF-1) in Adult Patients with Growth Hormone Deficiency (AGHD) |
| Rujia Xie Model-Based Drug Development (MBDD) of Pegylated Growth Hormone (PEG-hGH) in the Treatment of Adult Growth Hormone Deficient (AGHD) |
| Steven Xu Exposure-Response Analysis of Adverse Events in Clinical Trials Using Zero-Inflated Poisson Modeling With NONMEM®. |
| Stefano Zamuner Mixed Effects Markov Models for Modelling Sleep in Insomniac Patients Treated with Placebo in a 28 Days Trial: Emphasis on the Break Points Selection |
| Stefano Zamuner Adaptive Optimal Design in PET Occupancy Studies |
| Anthe Zandvliet PK-PD model of multiple follicular development with corifollitropin alfa during controlled ovarian stimulation: application of Markovian elements. |
| Wei Zhao Population Pharmacokinetics of Ganciclovir Following Oral Administration of its Prodrug Valganciclovir in Pediatric Renal Transplant Patients |
